Project Grant HT94252510343
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$1.7M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award of $793,572.00, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports a novel translational research study investigating the underlying pathophysiology of tuberous sclerosis complex (TSC) at Brigham & Women's Hospital. The award, with a performance period from August 2024 to August 2027, will fund cutting-edge research aimed at developing a better understanding of the mechanisms driving TSC,...
The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...
This federal Project Grant award of $855,709.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Brigham & Women's Hospital Inc. to target mitochondrial metabolism in Tuberous Sclerosis Complex. The 3-year project, running from September 1, 2023 to August 31, 2026, aims to transform healthcare for Service Members and the American public through innovative and impactful biomedical research on this rare...
The Defense Health Agency awarded a $772,626 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, effective from August 1, 2025 to July 31, 2028, will fund preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM). Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston,...
The Department of the Army Medical Command awarded a $1,715,894 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program. The grant will fund research from August 1, 2022 to July 31, 2025 to target tuberous sclerosis complex (TSC) by developing mTORC1-specific bi-steric inhibitors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and...
This federal Project Grant award of $802,500.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports preclinical gene therapy studies in a mouse model of TSC2 at Baylor College of Medicine in Houston, TX. The award, effective May 1, 2025 through April 30, 2028, will fund advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The program typically supports a wide range of...
This $168,042 federal Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, for in vivo targeting of TFE3 dimerization partners in translocation renal cell carcinoma (RCC) research. The award period runs from August 1, 2025 to July 31, 2026. The grant supports advanced biomedical research initiatives focused on transforming...
This federal Project Grant award of $319,542.00, provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports research at Brigham & Women's Hospital Inc. to investigate the modulation of epigenetic regulators controlling pathogenic astrocytes for the treatment of multiple sclerosis (MS). The research aims to advance scientific understanding and develop innovative therapeutic approaches for this chronic neurological...
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...